Investigational Drug Information for Henagliflozin
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Henagliflozin?
Henagliflozin is an investigational drug.
There have been 6 clinical trials for Henagliflozin.
The most recent clinical trial was a Phase 1 trial, which was initiated on May 1st 2022.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Atrial Fibrillation, and [disabled in preview]. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Beijing Anzhen Hospital, and [disabled in preview].
There are three US patents protecting this investigational drug and thirty-five international patents.
Summary for Henagliflozin
| US Patents | 3 |
| International Patents | 35 |
| US Patent Applications | 6 |
| WIPO Patent Applications | 12 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 1 (2022-05-01) |
| Vendors | 3 |
Recent Clinical Trials for Henagliflozin
| Title | Sponsor | Phase |
|---|---|---|
| Henagliflozin in Patients With Atrial Fibrillation | Beijing Anzhen Hospital | Phase 3 |
| Drug-drug Interaction Between Simvastatin and SHR3824 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| The Drug-drug Interaction of SHR3824 and SP2086 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
Clinical Trial Summary for Henagliflozin
Top disease conditions for Henagliflozin
Top clinical trial sponsors for Henagliflozin
US Patents for Henagliflozin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Henagliflozin | See Plans and Pricing | L-proline complex of sodium-glucose cotransporter 2 inhibitor, monohydrate and crystal form thereof | Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, Jiangsu, CN) | See Plans and Pricing |
| Henagliflozin | See Plans and Pricing | Compounds as peptidic GLP1/glucagon/GIP receptor agonists | SANOFI (Paris, FR) | See Plans and Pricing |
| Henagliflozin | See Plans and Pricing | Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists | SANOFI (Paris, FR) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Henagliflozin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Henagliflozin | Brazil | BR112017005454 | 2034-09-30 | See Plans and Pricing |
| Henagliflozin | Canada | CA2961819 | 2034-09-30 | See Plans and Pricing |
| Henagliflozin | China | CN105992769 | 2034-09-30 | See Plans and Pricing |
| Henagliflozin | European Patent Office | EP3202772 | 2034-09-30 | See Plans and Pricing |
| Henagliflozin | Spain | ES2836099 | 2034-09-30 | See Plans and Pricing |
| Henagliflozin | Hungary | HUE052588 | 2034-09-30 | See Plans and Pricing |
| Henagliflozin | Japan | JP2017530107 | 2034-09-30 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
